Skip to main content

Table 1 Baseline and clinical characteristics by BMI categories

From: Body mass index modifies the major adverse cardiovascular and cerebral events risk of NT-proBNP in patients with acute coronary syndrome

 

Whole cohort

(n = 11,757)

BMI 18.5–23.9 kg/m2 (n = 3477)

BMI 24.0–27.9 kg/m2

(n = 5386)

BMI ≥ 28.0 kg/m2

(n = 2894)

P value

Clinical characteristics

     

Age, years

65.1 ± 10.9

67.2 ± 10.8

65.0 ± 10.5

62.9 ± 11.4

< 0.001

Men, n (%)

7708 (65.6)

2173 (62.5)

3635 (67.5)

1900 (65.7)

< 0.001

Diabetes, n (%)

5332 (49.3)

1412 (44.8)

2473 (49.7)

1447 (53.8)

< 0.001

Previous hypertension, n (%)

8233 (70.0)

2142 (61.6)

3829 (71.1)

2262 (78.2)

< 0.001

Previous dyslipidemia, n (%)

5605 (47.7)

1523 (43.8)

2585 (48.0)

1497 (51.7)

< 0.001

Previous MI, n (%)

1089 (9.3)

327 (9.4)

521 (9.7)

241 (8.3)

0.12

Previous arrhythmia

1267 (10.8)

379 (10.9)

554 (10.3)

334 (11.5)

0.21

Current smoker, n (%)

4177 (35.5)

1218 (35.0)

1961 (36.4)

998 (34.5)

< 0.001

STEMI, n (%)

1990 (16.9)

634 (18.2)

926 (17.2)

430 (14.9)

< 0.001

LM or multivessel disease, n (%)

7788 (66.2)

2187 (62.9)

3669 (68.1)

1932 (66.8)

< 0.001

LVEF, %

63.3 ± 9.2

63.0 ± 10.0

63.4 ± 9.1

63.5 ± 8.5

0.10

Heart rate, bpm

72.2 ± 13.1

72.4 ± 14.1

72.1 ± 12.7

72.3 ± 12.5

0.51

SBP, mmHg

131.7 ± 18.7

130.4 ± 18.9

131.7 ± 18.5

133.0 ± 18.5

< 0.001

Laboratory values

     

Peak value of NT-proBNP, pg/ml

244.0 (82.0, 1087.0)

324.0 (96.3, 1619.0)

236.0 (79.4, 986.0)

196.0 (68.9, 792.0)

< 0.001

FPG, mmol/L

6.3 ± 2.3

6.1 ± 2.4

6.3 ± 2.2

6.4 ± 2.3

< 0.001

Hemoglobin, g/L

134.3 ± 19.4

131.0 ± 19.4

135.2 ± 19.0

136.6 ± 19.6

< 0.001

Hs-CRP, mg/L

2.1 (0.8, 7.4)

1.7 (0.6, 7.3)

2.1 (0.8, 7.1)

2.6 (1.1, 8.0)

< 0.001

Total cholesterol, mmol/L

4.27 ± 1.07

4.24 ± 1.04

4.28 ± 1.08

4.29 ± 1.08

0.12

LDL-C, mmol/L

2.42 ± 0.77

2.38 ± 0.76

2.44 ± 0.77

2.45 ± 0.76

< 0.001

HDL-C, mmol/L

1.08 ± 0.26

1.14 ± 0.28

1.06 ± 0.25

1.04 ± 0.25

< 0.001

Triglyceride, mmol/L

1.36 (1.01, 1.94)

1.19 (0.88, 1.65)

1.40 (1.04, 2.02)

1.54 (1.15, 2.14)

< 0.001

eGFR, ml/min/1.73m2

112.4 ± 30.9

112.3 ± 31.9

112.7 ± 30.5

112.0 ± 30.7

0.62

Inpatient treatment

     

Aspirin, n (%)

10,597 (90.1)

3055 (87.9)

4911 (91.2)

2631 (90.9)

< 0.001

Clopidogrel/Ticagrelor, n (%)

7162 (60.9)

2092 (60.2)

3345 (62.1)

1725 (59.6)

0.047

ACEI/ARB, n (%)

6442 (54.8)

1656 (47.6)

2967 (55.1)

1819 (62.9)

< 0.001

β-blocker, n (%)

7944 (67.6)

2241 (64.5)

3691 (68.5)

2012 (69.5)

< 0.001

Statins, n (%)

10,367 (88.2)

3015 (86.7)

4789 (88.9)

2563 (88.6)

0.006

PCI, n (%)

6451 (54.9)

1813 (52.1)

3060 (56.8)

1578 (54.5)

< 0.001

  1. Values are n (%), mean (SD), or median (interquartile interval). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LM, left main coronary artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment elevated myocardial infarction
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us